论文部分内容阅读
目的:为了建立确认荷兰医生对活动性结核病报告的方法。 方法:以服用化疗药物吡嗪酰胺作为结核病发生的标志。根据发给门诊病人吡嗪酰胺的每日剂量(DDD)来估计1994-1998年期间荷兰结核病患者的数量。DDD是一个测量的技术单位,不必须反映推荐或者实际应用的剂量。通常它的主要指标是以具有正常器官功能成人的平均每日剂量为基础。荷兰医疗保险部(CVZ)的药物信息规划部门(GIP)提供DDD资料。以通报给荷兰结核病登记处(NTR)的结核病患者为基础,按照这些病人的体重计算他们应该服用多少吡嗪酰胺(测量DDD)。 结果:按照GIP药房记录的DDD数量与通告给NTR计算出的DDD的数量只相差8％;登记的病人数应该是6889,而不是6349。 结论:GIP和NTR测量的吡嗪酰胺用量的非常接近,有力地证明荷兰报告的结核病与应报告的疾病指标相符。这种方法使用简便并且值得在其他国家推广。
Purpose: To establish a method of confirming Dutch doctors’ reporting of active tuberculosis. Methods: taking pyrazinamide chemotherapy as a marker of tuberculosis. The number of Dutch tuberculosis patients in the period 1994-1998 was estimated on the basis of the daily dose of pyrazinamide (DDD) given to the outpatient. DDD is a technical unit of measurement and does not necessarily reflect the recommended or actual dose. Usually its main indicator is based on the average daily dose of adults with normal organ function. The DDD information is provided by the Drug Information Planning Unit (GIP) of the Netherlands Department of Medicines (CVZ). Based on the TB patients notified to the Netherlands Tuberculosis Registry (NTR), how much pyrazinamide they should take (measurement of DDD) should be based on the weight of these patients. Results: The number of DDDs recorded according to the GIP pharmacy differs only by 8% from the number of DDDs notified to NTR; the number of patients registered should be 6889 instead of 6349. CONCLUSIONS: The use of pyrazinamide measured by GIP and NTR is very close and strongly confirms that the reported tuberculosis in the Netherlands is consistent with the reported disease index. This method is easy to use and worth promoting in other countries.